BioIVT, a global leader in biospecimen solutions and research support for drug and diagnostic development, announced that it will feature its expansive portfolio of cellular solutions at several major cell and gene therapy (CGT) conferences this fall. Among these, the company will play a prominent role at the 2025 Cell & Gene Meeting on the Mesa, widely recognized as one of the industry’s most influential gatherings for advancing cell and gene therapy research toward clinical application.
Highlighting Cellular Innovation at the Meeting on the Mesa
The Meeting on the Mesa, held from October 6–8, 2025, in Phoenix, Arizona, brings together top scientists, biotechnology executives, investors, and regulatory leaders to discuss innovations transforming cell and gene therapy. At booth #F13, BioIVT experts will showcase the company’s latest capabilities that accelerate research from discovery through clinical phases.
Central to BioIVT’s offering is its global network of donor centers, providing researchers with access to a diverse pool of highly characterized and recallable donors. These donors play a crucial role in supporting both early-stage research and late-phase development, enabling scientists to obtain consistent, high-quality cellular material that reflects real-world biological diversity.
Through its expanding CGT portfolio, BioIVT delivers a wide range of immune cell products, leukopaks, and disease-state materials tailored to meet the evolving needs of cell therapy developers. These solutions help bridge the critical gap between bench-scale experiments and large-scale clinical manufacturing, ensuring reliability and regulatory compliance at every stage of development.
A Creative Twist: “The Art of CGT” Returns with a New Theme
Beyond its scientific and technical contributions, BioIVT is known for bringing an artistic and human-centered dimension to the scientific community. The company’s much-anticipated Serenity Suite will return at this year’s Meeting on the Mesa as a dedicated space for attendees to rest, recharge, and connect.
As part of its ongoing “Art of CGT” campaign, the 2025 Serenity Suite will debut a new theme: “The Art of You.” This initiative celebrates scientists as artists—visionaries shaping the future of medicine through creativity, precision, and persistence. Visitors are invited to share their personal stories through a short form and visit BioIVT’s private studio in the Serenity Suite. Their narratives and likenesses will inspire a personalized, reimagined portrait painted in the style of their favorite artist.
The first 50 participants to request a framed copy of their custom artwork will receive a complimentary version after the event—a unique keepsake symbolizing their role in advancing the frontiers of science.
“Our commitment to advancing cell therapy innovation begins with the researchers we serve,” said Charlie Chungu, Vice President of Marketing at BioIVT. “We view these scientists as visionaries who drive life-changing breakthroughs. Our goal is to provide the high-quality cellular solutions that empower their discoveries. The Serenity Suite and the Art of CGT campaign are ways for us to honor their dedication while offering a creative space for inspiration and connection.”
Expanding Presence Across Global CGT Events
In addition to the Meeting on the Mesa, BioIVT will have a strong presence at several other CGT-focused events across North America and Europe this fall. These engagements underscore the company’s growing role as a trusted partner in the development and manufacture of next-generation therapies.
1. Raw Materials for Cell and Gene Therapy
Location: Boston, MA
Dates: October 7–9, 2025
Booth: #2
At this event, BioIVT will highlight its comprehensive range of immune cell products derived from healthy, disease-state, and autoimmune donors. Attendees will also learn about the company’s fresh and cryopreserved GMP-compliant leukopaks, which are designed to support clients across every stage of therapeutic development—from preclinical research to commercialization.
These products are central to ensuring consistency and safety in cell therapy manufacturing workflows, where high-quality donor material and traceable sourcing are critical for regulatory compliance and successful therapeutic outcomes.
2. European Society of Cell and Gene Therapy (ESGCT) Annual Meeting
Location: Seville, Spain
Dates: October 7–10, 2025
Booth: #D20
As BioIVT continues to expand its global reach, its participation in the ESGCT meeting reflects a strategic effort to strengthen its European partnerships. Attendees will learn how BioIVT’s European cellular logistics network enables rapid access to fresh and cryopreserved starting materials sourced from qualified donors across the continent.
By combining local accessibility with rigorous quality standards, BioIVT helps CGT developers streamline operations and reduce time-to-clinic in a market that is seeing significant regulatory evolution and accelerated investment in advanced therapies.
3. 3rd Annual Donor Selection & Cell Source Summit
Location: San Diego, CA
Dates: November 19–20, 2025
At this specialized forum, BioIVT experts will engage in discussions focused on donor management strategies, risk mitigation, and ethical sourcing of cellular materials—topics that are increasingly critical as the CGT field scales up to meet clinical and commercial demand.
Through interactive panels and networking sessions, BioIVT will share insights from its extensive donor network and its best practices in ensuring compliance, traceability, and reproducibility in cell sourcing.
Supporting the Future of Cell and Gene Therapy
BioIVT’s participation in these global events highlights its integrated role in the rapidly evolving CGT ecosystem. The company’s end-to-end solutions—spanning donor recruitment, biospecimen collection, cell isolation, cryopreservation, and logistics—position it as a partner of choice for organizations advancing innovative therapeutics.
By combining scientific rigor with a creative spirit, BioIVT continues to strengthen its reputation not only as a supplier of critical research materials but also as a champion of the scientists and innovators who bring cell and gene therapies to life.
As the CGT industry enters a new phase of clinical maturity and commercial readiness, BioIVT remains dedicated to providing the foundational tools, global infrastructure, and collaborative partnerships needed to power the next generation of life-changing treatments.
